)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Lantheus
Lantheus (LNTH) investor relations material
Lantheus Proxy filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Proxy filing summary2 Oct, 2026
Executive summary
Merger Agreement signed Aug. 3, 2026: Merger Sub will merge into the issuer, which will survive as a wholly owned subsidiary of Parent, subject to closing conditions.
Supplemental proxy disclosures were issued amid merger-related litigation; the issuer denied the proxy was deficient and said disclosures were made without admitting liability or wrongdoing.
Voting matters and shareholder proposals
A special meeting is scheduled for Oct. 14, 2026, to vote on the Merger Agreement and related proposals.
Board of directors and corporate governance
Three lawsuits filed against the issuer and certain directors alleged proxy omissions or misstatements involving projections, Morgan Stanley’s fairness analyses and insider conflicts; plaintiffs seek to enjoin the merger pending further disclosure.
As of Sept. 30, 2026, 16 stockholder demand letters had been received, including two with draft complaints; additional demands or lawsuits may follow.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Lantheus
- Merger with Curium US Holdings LLC advances, pending regulatory and shareholder approval.LNTH
Proxy filing - Stockholders are urged to approve the proposed merger with Curium US Holdings LLC.LNTHProxy filing
- Shareholders to vote on $102.50 cash plus CVR merger; board unanimously recommends approval.LNTHProxy filing
- Shareholders to vote on merger creating a global radiopharmaceutical leader, closing in 2027.LNTHProxy filing
- Q2 2026 revenue up 2.7%, adjusted EPS $1.55, and merger with Curium valued up to $8B announced.LNTHQ2 2026
- Curium and Lantheus announce a merger to create a global leader in diagnostics and therapeutics.LNTHProxy filing
- Shareholders to receive $102.50 per share plus up to $12.00 in CVRs, pending milestone achievements.LNTHProxy filing
- Definitive merger agreement with Curium offers up to $114.50 per share, closing expected in H1 2027.LNTHProxy filing
- Curium to acquire Lantheus for up to $114.50/share, creating a global radiopharmaceutical leader.LNTHProxy filing
Next Lantheus earnings date
Q3 20265 Nov, 2026
Lantheus
Next Lantheus earnings date
Q3 20265 Nov, 2026
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Lantheus Holdings Inc. is a healthcare company specializing in diagnostic imaging and therapeutic solutions. The company develops and commercializes radiopharmaceuticals, contrast agents, and medical imaging products used in cardiology, oncology, and other critical care applications. Lantheus serves healthcare providers, hospitals, and imaging centers, focusing on technologies that enhance disease detection and patient management. Its portfolio includes products for nuclear medicine, ultrasound, and precision diagnostics. The company is headquartered in Bedford, Massachusetts, and its shares are listed on the NASDAQ.